Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study

•Cobimetinib plus atezolizumab did not improve PFS versus pembrolizumab monotherapy in BRAFV600 wild-type advanced melanoma.•Results were consistent across prespecified subgroups according to known prognostic factors.•Higher tumor mutational burden was associated with improved clinical outcomes in both treatment arms.•As expected, the combination was associated with a higher incidence of AEs than pembrolizumab monotherapy. BackgroundEmerging...